Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study

Francis J. Giles, Gianantonio Rosti, Photis Beris, Richard E. Clark, Philipp Le Coutre, Francois Xavier Mahon, Juan Luis Steegmann, Peter Valent, Giuseppe Saglio

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science